Beam Therapeutics posted a wider Q2 2026 net loss of USD 122.7 million, or USD 1.18 per share.
Revenue fell to USD 490,000 from USD 8.47 million a year earlier.
R&D spending dipped to USD 95.1 million, while G&A climbed to USD 31.9 million.
Cash position and pipeline updates
Cash, cash equivalents, and marketable securities totaled USD 1.2 billion; cash runway is expected into mid-2029, including a planned USD 200 million draw.
The first patient was dosed in the BEAM-302 global pivotal cohort.
Risto-cel dosing was completed in Phase 1/2 BEACON, with BLA submission expected as early as year-end 2026.
BEAM•
